Tag: herg screening industry trends

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

HERG Screening Market Set To Climb From $2.06 Billion In 2026 To $3.2 Billion By 2030

The herg screening market has experienced substantial expansion in recent times. Its valuation is projected to increase from $1.84 billion in 2025 to $2.06 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. This historical expansion is attributable to several factors, including an uptick in cardiac-related drug withdrawals, greater investment in preclinical safety studies, the flourishing of pharmaceutical R&D, the adoption of in-vitro ion channel assays, and enhanced understanding of drug-induced arrhythmias.

The herg screening market is poised for significant growth in the upcoming years. It is forecast to achieve a valuation of $3.21 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This expansion during the projection period can be credited to advances in AI-driven predictive toxicology, the adoption of organ-on-chip technologies, the increasing development of biologics and personalized medicine, a surge in outsourcing to CDMOs, and the expansion of preclinical research in emerging markets. Prominent trends anticipated in this period include enhanced cardiotoxicity modeling, automated high-throughput screening, the incorporation of predictive analytics in preclinical safety evaluations, an increase in contract research services, and the application of miniaturized microfluidic assays.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=75071351&type=smp&name=HERG%20Screening%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

HERG Screening Market Expansion Drivers: What’s Shaping Future Growth?

The increasing number of patients diagnosed with heart disorders is projected to boost the expansion of the HERG screening market moving forward. Heart disorders, also termed cardiovascular disorders or diseases, describe various conditions affecting the heart and blood vessels. These ailments can compromise the heart’s proper function and potentially lead to serious health complications. Such disorders stem from factors like unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening assists in identifying promising drug candidates, preventing adverse cardiac events that could provoke life-threatening cardiac arrhythmias, particularly torsade de pointes (TdP), and improving patient outcomes. For instance, in October 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, an estimated 57,100 adults aged 25 and above experienced acute coronary events, averaging approximately 156 incidents per day. Therefore, the growing incidence of patients with heart disorders is propelling the HERG screening market’s growth.

HERG Screening Market Segment Analysis: What Are The Core Market Categories?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

HERG Screening Market Strategic Trends: What Defines The Next Growth Phase?

Leading firms in the HERG screening market are concentrating on developing novel, advanced solutions, such as GLP-certified HERG screening services, to improve cardiac safety assessments during the drug development process. This particular service involves the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) employing the traditional whole-cell patch-clamp technique. It ensures adherence to regulatory guidelines like ICH S7A and ICH S7B, which are crucial for safety pharmacology studies within drug development. For instance, in August 2023, Metrion Biosciences Ltd., a pharmaceutical company based in the UK, introduced its good laboratory practice (GLP)-certified hERG screening service. This offering aims to strengthen Metrion’s support for the development of small-molecule therapeutics and expand its existing portfolio of cardiac safety services. Furthermore, this service leverages the conventional whole-cell patch-clamp technique to evaluate potential cardiac liabilities before human subjects enter Phase 1 clinical trials, provides regulatory advice for safety pharmacology studies in drug development, and delivers high-quality biology services to clients targeting ion channels.

HERG Screening Market Top Companies Driving Competitive Growth

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

View The Full HERG Screening Market Report:

https://thebusinessresearchcompany.com/report/herg-screening-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

HERG Screening Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

HERG Screening Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The herg screening market has experienced rapid expansion in recent years, with its size projected to increase from $1.84 billion in 2025 to $2.06 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. This historic growth has been driven by several factors, including a growing number of cardiac-related drug withdrawals, heightened investments in preclinical safety studies, an expansion in pharmaceutical research and development, wider adoption of in-vitro ion channel assays, and rising awareness surrounding drug-induced arrhythmias.

The hERG screening sector is forecasted to experience rapid expansion in the coming years, reaching a valuation of $3.21 billion by 2030, with a compound annual growth rate (CAGR) of 11.7%. Several factors are driving this growth in the projected timeframe, including progress in AI-based predictive toxicology, the adoption of organ-on-chip technologies, the rise of biologics and personalized medicine, increased outsourcing to contract development and manufacturing organizations (CDMOs), and the broadening of preclinical research activities in emerging markets. Key developments shaping the period ahead involve sophisticated cardiotoxicity modeling, automation of high-throughput screening processes, the integration of predictive analytics into preclinical safety assessments, the growth of contract research services, and the deployment of miniaturized microfluidic assays.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

HERG Screening Market Expansion Supported By Key Demand Factors

The growing prevalence of heart disorders is expected to drive the expansion of the HERG screening market in the coming years. Heart disorders, also referred to as cardiovascular diseases or conditions, encompass a variety of issues that affect the heart and blood vessels. These conditions can impair the heart’s normal function and lead to severe health problems, often stemming from unhealthy lifestyle choices, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening plays a crucial role in identifying potential drug candidates, reducing the risk of adverse cardiac events that might cause life-threatening arrhythmias such as torsade de pointes (TdP), and enhancing patient outcomes. For example, in October 2025, the Australian Institute of Health and Welfare, a government agency based in Australia, noted that in 2023, approximately 57,100 adults aged 25 and older experienced acute coronary events, averaging around 156 occurrences each day. Consequently, the increasing number of patients with heart disorders is fueling the growth of the HERG screening market.

The increase in the aging population is anticipated to fuel the growth of the HERG screening market moving forward. An aging population is characterized by a growing share of older people in a society, driven by longer life expectancies and lower birth rates. This demographic shift is occurring due to improved healthcare advancements that extend lifespan. HERG screening supports the aging population by ensuring that new medications are safe for elderly individuals, as it identifies compounds that may trigger dangerous cardiac side effects. For instance, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, reported that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, reflecting a 47% rise. Consequently, this age group’s share of the total U.S. population is expected to grow from 17% to 23% over that timeframe. Thus, the rise in the aging population is driving the growth of the HERG screening market.

HERG Screening Market Segments: Where Are The Largest Growth Opportunities?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

HERG Screening Market Growth Trends Influencing Competitive Dynamics

Leading industry players in the hERG screening market are placing significant emphasis on introducing innovative, advanced solutions—particularly GLP-certified hERG screening services—aimed at improving cardiac safety evaluations during drug development. Such a service involves conducting good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) through the standard whole-cell patch-clamp technique. This approach guarantees that screening procedures align with regulatory standards like ICH S7A and ICH S7B, crucial for safety pharmacology studies in the drug development process. For example, in August 2023, Metrion Biosciences Ltd., a pharmaceutical firm based in the UK, unveiled a GLP-certified hERG screening service. Designed to strengthen Metrion’s support for small-molecule therapeutic development, this offering also expands the company’s existing cardiac safety service portfolio. Moreover, the service employs the conventional whole-cell patch-clamp method to identify potential cardiac risks before human Phase 1 clinical trials, offers regulatory advice for safety pharmacology studies, and delivers high-quality biology services focused on ion channel targets to clients.

HERG Screening Market Major Participants And Competitive Dynamics

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

Access The Complete HERG Screening Market Report:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

HERG Screening Market Geographic Distribution And Regional Opportunities

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The HERG Screening Market Increase Between 2026 And 2030?

The herg screening market has experienced rapid expansion in recent years. It is projected to expand from $1.84 billion in 2025 to $2.06 billion in 2026, registering a compound annual growth rate (CAGR) of 12.0%. Historically, this market’s expansion has been propelled by factors such as a rise in cardiac-related drug withdrawals, increased investment in preclinical safety studies, the growth of pharmaceutical R&D, the adoption of in-vitro ion channel assays, and heightened awareness of drug-induced arrhythmias.

The herg screening market is anticipated to experience significant expansion over the coming years. This market is projected to reach $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This growth during the projection period stems from progress in AI-driven predictive toxicology, the incorporation of organ-on-chip technologies, the rise of biologics and personalized medicine, increased outsourcing to CDMOs, and the broadening of preclinical research in developing markets. Key trends anticipated for the forecast period encompass sophisticated cardiotoxicity modeling, the automation of high-throughput screening, the embedding of predictive analytics within preclinical safety assessments, the broadening of contract research services, and the development of miniaturized microfluidic assays.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Major Growth Factors Are Impacting The HERG Screening Market?

The HERG screening market is anticipated to expand due to an increase in patients suffering from heart disorders. These conditions, also known as cardiovascular diseases, encompass various ailments impacting the heart and blood vessels, potentially impairing heart function and leading to severe health issues. Unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome contribute to these disorders. HERG screening plays a crucial role in identifying suitable drug candidates, averting serious cardiac incidents such as life-threatening cardiac arrhythmias, specifically torsade de pointes (TdP), and ultimately improving patient health. For example, the Australian Institute of Health and Welfare, an Australian government body, indicated in October 2025 that an estimated 57,100 adults aged 25 and above experienced acute coronary events in 2023, averaging approximately 156 incidents daily. Consequently, the growing prevalence of heart disorder patients is a key driver for the HERG screening market. The expanding aging population is projected to stimulate the growth of the HERG screening market moving ahead. An aging population signifies an increasing segment of older individuals within a community, largely attributed to longer life expectancies and decreased birth rates, with healthcare advancements playing a key role in extending lives. HERG screening is vital for this demographic, as it helps ascertain the safety of new medications for elderly patients by pinpointing compounds that might induce adverse cardiac effects. For instance, the US-based Population Reference Bureau stated in January 2024 that the number of Americans aged 65 and above is anticipated to climb from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Consequently, this age group’s share of the overall U.S. population is set to increase from 17% to 23% over this timeframe. Hence, the increasing aging population is a significant factor driving the HERG screening market.

How Is Segment Classification Applied In The HERG Screening Market?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

What Trends Are Driving Changes In The HERG Screening Market?

Leading companies in the HERG screening market are concentrating on advanced, innovative solutions, notably GLP-certified HERG screening services, to enhance cardiac safety evaluations throughout drug development. This specific service involves the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) employing the standard whole-cell patch-clamp technique. Its purpose is to ensure adherence to regulatory guidelines such as ICH S7A and ICH S7B, which are critical for safety pharmacology studies during drug development. An example is Metrion Biosciences Ltd., a UK-based pharmaceutical company, which introduced its good laboratory practice (GLP)-certified hERG screening service in August 2023. This offering seeks to bolster Metrion’s support for small-molecule therapeutic development and complement its existing cardiac safety service portfolio. Furthermore, this service uses the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities prior to human Phase 1 clinical trials, provides regulatory guidance for safety pharmacology studies in drug development, and offers clients high-quality biology services for ion channel targets.

Who Are The Prominent Players Across The HERG Screening Market?

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

Access The Complete HERG Screening Market Report:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Which Region Holds The Largest Share In The HERG Screening Market?

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access HERG Screening Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Browse Through More Reports Similar to the Global HERG Screening Market 2026, By The Business Research Company

Herg Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Cellular Health Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Carrier Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The HERG Screening Market Be By 2030 Compared To Its 2026 Market Size?

The herg screening market has seen a rapid increase in size over recent years. It is anticipated to expand from $1.84 billion in 2025 to $2.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. The historical growth trajectory is largely due to factors such as an increase in cardiac-related drug withdrawals, enhanced investment in preclinical safety studies, the expansion of pharmaceutical R&D, the implementation of in-vitro ion channel assays, and heightened awareness concerning drug-induced arrhythmias.

The herg screening market is anticipated to experience significant expansion over the coming years, with its size projected to reach $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This growth during the forecast period is attributable to progress in AI-driven predictive toxicology, the incorporation of organ-on-chip technologies, the increasing development of biologics and personalized medicine, a rise in outsourcing to CDMOs, and the expansion of preclinical research in developing markets. Key trends identified for this period encompass sophisticated cardiotoxicity modeling, automated high-throughput screening, the embedding of predictive analytics within preclinical safety assessments, an increase in contract research services, and the use of miniaturized microfluidic assays.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Which Factors Are Influencing The Growth Of The HERG Screening Market?

An increasing prevalence of individuals suffering from heart ailments is anticipated to boost the expansion of the HERG screening market. Cardiovascular disorders, also known as heart diseases, encompass various conditions impacting the heart and blood vessels, potentially impairing heart function and leading to severe health issues. Factors contributing to these conditions include unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening plays a crucial role in identifying suitable drug candidates, thereby preventing serious cardiac events such as life-threatening arrhythmias, notably torsade de pointes (TdP), and ultimately enhancing patient welfare. For example, the Australian Institute of Health and Welfare, an Australia-based government agency, reported in October 2025 that approximately 57,100 adults aged 25 and above experienced acute coronary events in 2023, averaging around 156 occurrences daily. Consequently, the growing number of patients with heart disorders is propelling the HERG screening market forward. The increasing proportion of older individuals in society is anticipated to propel the expansion of the HERG screening market. An aging population signifies a higher percentage of elderly people within a community, largely attributed to longer life expectancies and declining birth rates. Healthcare advancements, which have extended human lifespan, are a key factor in this demographic shift. HERG screening serves the aging demographic by ensuring the safety of novel pharmaceuticals for elderly patients, specifically by detecting compounds that might induce adverse cardiac effects. For instance, in January 2024, the Population Reference Bureau, a US-based non-profit organization, stated that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. During this timeframe, this cohort’s share of the total U.S. population is expected to grow from 17% to 23%. Consequently, the growing aging population is a significant catalyst for the HERG screening market.

How Are Segments Identified Within The HERG Screening Market Segment Framework?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

Which Trends Are Guiding The Direction Of The HERG Screening Market?

Leading companies in the HERG screening market are focusing on innovative advanced solutions, such as GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development processes. This service entails the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) utilizing the conventional whole-cell patch-clamp technique. It ensures that screening adheres to regulatory guidelines like ICH S7A and ICH S7B, which are vital for safety pharmacology studies in drug development. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched its good laboratory practice (GLP)-certified hERG screening service. This service aims to improve Metrion’s support for small-molecule therapeutic development and augment the company’s existing cardiac safety service portfolio. Moreover, this service employs the conventional whole-cell patch-clamp technique to evaluate potential cardiac liabilities before entering Phase 1 clinical trials in humans, offers regulatory guidance for safety pharmacology studies in drug development, and provides clients with high-quality biology services for ion channel targets.

Who Are The Companies Competing Within The HERG Screening Market?

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

Get The Full HERG Screening Market Report:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Where Is The HERG Screening Market Most Concentrated Geographically?

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized HERG Screening Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Browse Through More Reports Similar to the Global HERG Screening Market 2026, By The Business Research Company

Herg Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Cellular Health Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Carrier Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The HERG Screening Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The herg screening market size has experienced rapid growth over recent years. It is projected to increase from $1.84 billion in 2025 to $2.06 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. This historical expansion can be linked to a rise in cardiac-related drug withdrawals, heightened investment in preclinical safety studies, the ongoing development of pharmaceutical R&D, the utilization of in-vitro ion channel assays, and greater awareness concerning drug-induced arrhythmias.

The herg screening market is projected for substantial expansion over the upcoming years. Its valuation is anticipated to reach $3.21 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This projected growth during the forecast period is largely due to several factors, including developments in AI-driven predictive toxicology, the incorporation of organ-on-chip technologies, the proliferation of biologics and personalized medicine, an increase in outsourcing activities to CDMOs, and the broadening of preclinical research in developing markets. Key developments anticipated in this period encompass sophisticated cardiotoxicity modeling, automated high-throughput screening, the adoption of predictive analytics in preclinical safety evaluations, an increase in contract research services, and the use of miniaturized microfluidic assays.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Drivers Are Influencing The HERG Screening Market?

The HERG screening market is projected to grow as the number of individuals affected by heart disorders increases. These conditions, also referred to as cardiovascular disorders or diseases, encompass various ailments impacting the heart and blood vessels. Such conditions can hinder the heart’s proper functioning and potentially result in severe health complications. Unhealthy lifestyles, an aging population, genetic factors, diabetes, and metabolic syndrome are among the causes of these disorders. HERG screening assists in identifying suitable drug candidates, preventing adverse cardiac events that might induce life-threatening cardiac arrhythmias, particularly torsade de pointes (TdP), and improving patient outcomes. For instance, in October 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency reported that in 2023, an estimated 57,100 adults aged 25 and above experienced acute coronary events, averaging roughly 156 incidents per day. Therefore, the growing count of patients with heart disorders is propelling the expansion of the HERG screening market.

What Major Segment Divisions Exist Within The HERG Screening Market?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

How Are Trends Shaping The Direction Of The HERG Screening Market?

Leading companies operating in the HERG screening market are focusing on new, innovative advanced solutions, such as GLP-certified HERG screening services, to improve cardiac safety assessments during drug development processes. This service refers to the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the traditional whole-cell patch-clamp technique. It ensures that the screening is carried out in accordance with regulatory guidelines like ICH S7A and ICH S7B, which are crucial for safety pharmacology studies in drug development. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, introduced its good laboratory practice (GLP)-certified hERG screening service. This service aims to bolster Metrion’s support for small-molecule therapeutic development and enhance the company’s existing cardiac safety service portfolio. Additionally, this service employs the conventional whole-cell patch-clamp technique to evaluate potential cardiac liabilities before humans enter Phase 1 clinical trials, offers regulatory guidance for safety pharmacology studies in drug development, and provides clients with high-quality biology services for ion channel targets.

Which Companies Are Leading Innovation In The HERG Screening Market?

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

Read the full herg screening market report here:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The HERG Screening Market?

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored HERG Screening Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

Browse Through More Reports Similar to the Global HERG Screening Market 2026, By The Business Research Company

Herg Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Cellular Health Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Carrier Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the herg screening market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the HERG Screening Market covering 2026–2035?

The herg screening market size has seen swift expansion in recent years. It is anticipated to increase from $1.84 billion in 2025 to $2.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. This historical growth can be attributed to several factors such as the increasing occurrences of cardiac-related drug withdrawals, heightened investment in preclinical safety studies, the expansion of pharmaceutical R&D, the widespread adoption of in-vitro ion channel assays, and a growing understanding of drug-induced arrhythmias.

The herg screening market size is expected to undergo rapid expansion in the coming years, reaching $3.21 billion by 2030 with a compound annual growth rate (CAGR) of 11.7%. This projected growth is driven by advancements in AI-driven predictive toxicology, the integration of organ-on-chip technologies, the increasing prevalence of biologics and personalized medicine, a rise in outsourcing to CDMOs, and the expansion of preclinical research in emerging markets. Key trends identified for this forecast period include advanced cardiotoxicity modeling, automation in high-throughput screening, the integration of predictive analytics into preclinical safety, an increase in contract research services, and the development of miniaturized microfluidic assays.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The HERG Screening Market?

An increase in individuals suffering from heart conditions is anticipated to fuel the expansion of the HERG screening market in the future. Cardiovascular diseases, also referred to as heart disorders, encompass various conditions affecting the heart and its blood vessels. Such ailments can impair the heart’s proper functioning, potentially resulting in severe health issues. These conditions stem from factors like unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening assists in identifying promising drug candidates, averting dangerous cardiac events, specifically torsade de pointes (TdP), which can cause life-threatening heart rhythm problems, and enhancing results for patients. For instance, in October 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency reported that in 2023, an estimated 57,100 adults aged 25 and above experienced acute coronary events, averaging roughly 156 incidents per day. Consequently, the growing prevalence of patients with heart conditions is stimulating the expansion of the HERG screening market.

What Leading Segments Are Studied In The HERG Screening Market?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

What Trends Are Reshaping The Dynamics Of The HERG Screening Market?

Leading companies in the HERG screening market are directing their efforts towards innovative advanced solutions, including GLP-certified HERG screening services, to improve cardiac safety evaluations throughout drug development. This service specifically involves the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) utilizing the standard whole-cell patch-clamp technique. Its purpose is to guarantee that screenings comply with regulatory guidelines, such as ICH S7A and ICH S7B, which are vital for safety pharmacology investigations in drug development. An example of this trend is Metrion Biosciences Ltd., a UK-based pharmaceutical company, which introduced its good laboratory practice (GLP)-certified hERG screening service in August 2023. This offering is designed to strengthen Metrion’s assistance for small-molecule therapeutic development and complement the company’s existing portfolio of cardiac safety services. Furthermore, this service employs the conventional whole-cell patch-clamp technique to identify potential cardiac risks before human Phase 1 clinical trials, delivers regulatory advice for safety pharmacology studies in drug development, and provides clients with high-quality biology services concerning ion channel targets.

Which Leading Companies Dominate The HERG Screening Market Share?

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

How Does The HERG Screening Market Perform Across Major Global Regions?

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized HERG Screening Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

Browse Through More Reports Similar to the Global HERG Screening Market 2026, By The Business Research Company

Herg Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Cellular Health Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Carrier Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the herg screening market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The HERG Screening Market Size?

The HERG screening market size has experienced rapid expansion in recent years. Its value is expected to rise from $1.62 billion in 2024 to $1.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.7%. This historical growth can be attributed to an increase in drug development activities, regulatory requirements, heightened awareness of cardiac safety, and a growing incidence of cardiac disorders.

The HERG screening market is anticipated to expand significantly in the near future, with projections showing it will reach $2.88 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.9%. This upward trend during the forecast period is primarily driven by the proliferation of personalized medicine, an increase in outsourced drug development tasks, the rise of new markets and research efforts, and a renewed emphasis on non-cardiac safety assessments. Dominant trends for this period are expected to encompass advanced in vitro models, the merging of genomic and proteomic information, progress in computational techniques, a specific focus on pediatric drug safety, and collaborative initiatives for data exchange and standardization.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Core Market Drivers Are Expanding The HERG Screening Industry?

The increasing number of individuals afflicted with heart disorders is expected to propel the expansion of the HERG screening market in the future. Heart disorders, also known as cardiovascular disorders or diseases, refer to a spectrum of conditions that impact the heart and blood vessels. These conditions can impair the heart’s ability to function correctly and potentially lead to serious health complications. Such disorders often arise due to unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome. HERG screening assists in identifying promising drug candidates, preventing adverse cardiac events that could induce life-threatening cardiac arrhythmias, particularly torsade de pointes (TdP), and enhancing patient outcomes. For instance, in May 2023, a report published by the Centers for Disease Control and Prevention, a US-based national public health agency, indicated that 1 in 20 adults aged 20 and above have cardiovascular diseases, with 695,000 people suffering from these diseases and 375,476 people dying from them. Furthermore, in March 2022, according to a report from the Office for National Statistics, a UK-based government department, 20,061 individuals died of heart attacks, marking an increase from the prior year. Consequently, the rising incidence of heart disorders among patients is driving the growth of the HERG screening market.

What Segment Insights Are Highlighted In The HERG Screening Market Report?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

Which Notable Trends Are Transforming The HERG Screening Market Outlook?

Major companies operating in the HERG screening market are focusing on new innovative advanced solutions, such as GLP-certified HERG screening services, to enhance cardiac safety assessments during drug development. This service involves the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) utilizing the conventional whole-cell patch-clamp technique. It ensures the screening is conducted in compliance with regulatory guidelines like ICH S7A and ICH S7B, which are vital for safety pharmacology studies in drug development. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched its good laboratory practice (GLP)-certified hERG screening service. This service aims to bolster Metrion’s support for small-molecule therapeutic development and complement the company’s existing cardiac safety service portfolio. Additionally, this service employs the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before entering Phase 1 clinical trials in humans, provides regulatory guidance for safety pharmacology studies in drug development, and offers clients high-quality biology services for ion channel targets.

Which Firms Are Driving Innovation Within The HERG Screening Market?

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

What Regional Trends Are Shaping Growth In The HERG Screening Market?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

Browse Through More Reports Similar to the Global HERG Screening Market 2025, By The Business Research Company

Carrier Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Blood Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Airport Baggage Screening Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/airport-baggage-screening-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The HERG Screening Market?

The HERG screening market size has observed swift expansion in recent years. It is anticipated to grow from $1.62 billion in 2024 to $1.84 billion in 2025, maintaining a compound annual growth rate (CAGR) of 13.7%. This historic growth is linked to factors such as increasing drug development activities, stricter regulatory requirements, heightened awareness of cardiac safety, and a rising incidence of cardiac disorders.

The HERG screening market size is anticipated to undergo significant expansion in the next few years. It is predicted to reach “$2.88 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 11.9%”. This growth throughout the forecast period can be attributed to several factors, including the proliferation of personalized medicine, an increase in the outsourcing of drug development activities, advancements in emerging markets and research, and a heightened focus on non-cardiac safety assessments. Major trends identified for the forecast period encompass the development of advanced in vitro models, the integration of genomic and proteomic data, ongoing advancements in computational approaches, a dedicated focus on pediatric drug safety, and collaborative efforts for data sharing and standardization.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Which Drivers Are Impacting The HERG Screening Market?

The HERG screening market is projected to expand due to the increasing number of patients diagnosed with heart disorders. These conditions, also known as cardiovascular disorders or diseases, encompass a variety of ailments affecting the heart and its blood vessels. Such disorders can impede the heart’s ability to function correctly and potentially lead to serious health complications. They are often attributed to unhealthy lifestyles, an aging population, genetic factors, diabetes, and metabolic syndrome. HERG screening plays a vital role in identifying prospective drug candidates, preventing adverse cardiac events that might induce life-threatening cardiac arrhythmias, especially torsade de pointes (TdP), and enhancing patient outcomes. For instance, in May 2023, a report published by the Centers for Disease Control and Prevention, a US-based national public health agency, indicated that 1 in 20 adults aged 20 and above suffer from cardiovascular diseases, with 695,000 individuals impacted and 375,476 deaths attributed to these conditions. Additionally, in March 2022, data from the Office for National Statistics, a UK-based government department, revealed 20,061 fatalities from heart attacks, marking an increase from the previous year. Consequently, the rising prevalence of patients with heart disorders is a significant factor driving the growth of the HERG screening market.

What Are The Major Segment Types Covered In The HERG Screening Market?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

What Are The Major Trends Driving The Growth Of The HERG Screening Market?

Leading firms within the HERG screening market are concentrating on advanced and innovative solutions, such as GLP-certified HERG screening services, to enhance cardiac safety assessments throughout drug development processes. This service entails the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the established whole-cell patch-clamp technique. It ensures that the screening adheres to regulatory guidelines like ICH S7A and ICH S7B, which are crucial for safety pharmacology studies in drug development. For instance, in August 2023, Metrion Biosciences Ltd., a UK-based pharmaceutical company, launched its good laboratory practice (GLP)-certified hERG screening service. This offering is designed to bolster Metrion’s support for small-molecule therapeutic development and complement the company’s existing cardiac safety service portfolio. Additionally, this service utilizes the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities before entering Phase 1 clinical trials in humans, provides regulatory guidance for safety pharmacology studies in drug development, and offers clients high-quality biology services for ion channel targets.

Who Are The Key Multinational Companies Dominating The HERG Screening Market?

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The HERG Screening Market?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The HERG Screening Market Report:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

Browse Through More Reports Similar to the Global HERG Screening Market 2025, By The Business Research Company

Carrier Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Blood Screening Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report

Airport Baggage Screening Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/airport-baggage-screening-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The HERG Screening Market Expected To Grow In Terms Of Size?

The market size for HERG screening has significantly expanded in the last few years. It is projected to increase from $1.62 billion in 2024 to $1.84 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.7%. The escalation during the historic period is due to a surge in drug development activities, regulatory directives, a growing consciousness about cardiac safety, and an upward trend in cardiac disorder incidents.

In the coming years, the HERG screening market size is anticipated to witness a remarkable expansion. The market is projected to reach “$2.88 billion by 2029 with a compound annual growth rate (CAGR) of 11.9%. The forecasted growth is largely linked to the broadening scope of personalized medicine, an increase in the delegation of drug development tasks, the rise of emerging markets, as well as research and focus on non-cardiac safety assessments. Key emerging trends for the predicted period include advancements in in vitro models, incorporation of genomic and proteomic data, progression in computational methods, emphasis on pediatric drug safety, and collaborations aimed at data sharing and standardization.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Which Factors Are Steering Growth In The HERG Screening Market?

The increasing prevalence of cardiac conditions is anticipated to drive the expansion of the HERG screening market. Also known as cardiovascular diseases, heart disorders encompass a series of ailments influencing the heart and blood vessels. These maladies can disrupt the functioning of the heart and potentially lead to severe health issues. Unhealthy lifestyles, elderly population, genetics, diabetes, and metabolic syndrome are central to the emergence of these disorders. HERG screening assists in recognizing potential pharmaceutical candidates, warding off dangerous cardiac incidents like life-threatening cardiac arrhythmias, especially torsade de pointes (TdP), and enhancing patient prognosis. For example, a report by the US-based Centers for Disease Control and Prevention in May 2023 revealed that 1 in 20 adults over the age of 20 have cardiovascular diseases, with 695,000 people diagnosed and 375,476 deaths. Additionally, a March 2022 report from the UK’s Office for National Statistics showed that 20,061 people died from heart attacks, marking an uptick from the prior year. Thus, the growing count of heart disorder patients is fueling the advancement of the HERG screening market.

How Is The HERG Screening Market Segmented Across Key Categories?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

What Key Trends Are Driving Growth In The HERG Screening Market?

Key players in the HERG screening market are focusing on developing new cutting-edge solutions such as GLP-certified HERG screening services, to improve cardiac safety evaluations in drug development procedures. These services involve the GLP-approved screening of the human ether-à-go-go related gene (hERG) using the traditional whole-cell patch-clamp method, ensuring the screening aligns with regulatory guidelines like ICH S7A and ICH S7B, integral for safety pharmacology research in drug development. For example, in August 2023, Metrion Biosciences Ltd., a British pharmaceutical firm, introduced its GLP-certified hERG screening service. The purpose of this service is to expand Metrion’s aid for the development of small molecule therapeutics and supplement the firm’s current cardiac safety service range. Moreover, this service uses the traditional whole-cell patch-clamp technique to evaluate potential cardiac risks before the initiation of Phase 1 clinical trials in humans, delivers regulatory advice for safety pharmacology research in drug development, and gives clients top-notch biology services for ion channel targets.

Which Firms Are Driving Innovation Within The HERG Screening Market?

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

How Do Regional Dynamics Influence The HERG Screening Market Performance?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model